Navigation Links
New Pill for MS Shows Promise in Clinical Trial
Date:4/12/2011

an Academy of Neurology meeting.

In the two-year, double-blind Phase III trial, participants were randomly divided into two groups: those who were given a daily dose of laquinimod (0.6 milligrams) and those who were given a sugar-pill (placebo); neither the researchers nor the participants knew who received the medication or the placebo.

The annual rate of MS relapse was 23 percent lower in the laquinimod group compared with the placebo group.

In addition, disability progression was reduced by 36 percent and brain atrophy by 33 percent compared with those getting the sham treatment.

Adverse events, including serious events, were comparable to those in the placebo group, according to the researchers. The incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.

Laquinimod was not, however, tested against currently existing treatment alternatives, the authors stressed. The team added that the new medication appears to tackle MS by a different type of mechanism than other available options, and apparently works by curtailing the onset of permanent tissue damage while limiting acute inflammation.

"Each of the medications we have has a different mechanism of action," explained Dr. Gary Birnbaum, director of the MS Treatment and Research Center at the Minneapolis Clinic of Neurology. "And MS is probably not a single disease. So different medications may work better for some and not others, which is why this new drug could end up being an important addition to the armamentarium."

"However, we still need to have a head-to-head comparison with other drugs," cautioned Birnbaum, who was not part of the study team. "This is not that. And it's also important to note that this is not a cure. It achieved a reduction in the annualized relapse rate, and people on this medication did not hav
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. First blinded study of venous insufficiency prevalence in MS shows promising results
2. People with anxiety disorder less able to regulate response to negative emotions, study shows
3. Poll Shows Eroding Support for Health Reform
4. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
5. Compound shows promise against intractable heart failure
6. Drama or reality TV: Do medical shows depict proper first aid for seizures?
7. TV Shows Often Botch Proper Seizure Responses
8. UQ research shows canecutters disease on the rise among travelers
9. Brain Scan Shows What Beauty is Worth
10. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
11. New research shows emotional impact of low sexual desire and associated distress
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Pill for MS Shows Promise in Clinical Trial
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to WFLA on ... of heroin use and eventual overdoses. Thricefold deaths have held steady over the last ... on the Sarasota heroin epidemic, which was spurred by the crackdown of prescription painkillers. ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... Practice, Pediatric Emergency Medicine Practice, and Hospital Medicine Practice, is pleased to announce ... in a mobile application format available on iPhones, iPads, and Android smartphones ...
(Date:7/31/2015)... ... July 31, 2015 , ... An article entitled " ... about a woman’s unfortunate experience having cosmetic skin procedures done by a family ... in blistering, swelling, bruising, and pain. This woman’s experience is only one in ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... a wide variety of nutritional and wellness products, announced the addition of Vincent ... in massage therapy, active isolated stretching and the prevention and rehabilitation of injuries, ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2
... a large multi-center clinical trial, a new PSA test ... with prostate cancer -- particularly the aggressive form of ... to the two,currently available commercial PSA tests, according to ... currently available Food and Drug Administration-approved screening tests for ...
... Research institutions at 27 sites in the U.S. ... Cancer Immunotherapy Trials Network (CITN), a new initiative in ... at Fred Hutchinson Cancer Research Center. CITN will establish ... research on promising new agents that boost patients, own ...
... Mo. - Youths identified as American Indian or Alaska ... all racial groups, according to the Department of Health ... AI/AN youths in the U.S. smoke cigarettes. A University ... combat smoking should teach refusal skills to help youths ...
... , WEDNESDAY, April 6 (HealthDay News) -- Poor children with ... condition diagnosed, but this disparity has decreased in recent years, ... children in California and found that the average age of ... 1992 to 3.8 years for those born in 2000. ...
... , WEDNESDAY, April 6 (HealthDay News) -- Progesterone treatment lowers ... cervix, a new study shows. Progesterone is a naturally ... It,s believed that a short cervix -- a known risk ... a shortage of progesterone. This study included 458 women ...
... April 5 White House Press Briefing, President Barack Obama articulated ... Congress from both political parties in order to avoid a ... has matched the initial House of Representatives, proposal to make ... in areas of priority. He expressed that neither side would ...
Cached Medicine News:Health News:New prostate cancer test gives more accurate diagnosis 2Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 2Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 3Health News:Fred Hutchinson Cancer Research Center to lead Immunotherapy Clinical Trials Network 4Health News:Refusal skills help minority youths combat smoking, study finds 2Health News:Autism Diagnoses Still More Likely in Richer Neighborhoods 2Health News:Progesterone Treatment Cuts Preterm Birth Risk in Certain Women 2Health News:AADR applauds President Obama's support for maintaining biomedical research in FY11 2
(Date:7/31/2015)... Inc. (Nasdaq: SMLR ), a company that provides ... groups, today reported financial results for the second quarter ... second quarter of 2015, Semler reported continued progress with ... quarter revenue growth of 8%, and quarter over quarter ... 18%," said Doug Murphy-Chutorian, M.D., chief executive officer of ...
(Date:7/31/2015)... July 31, 2015  Xencor, Inc. (NASDAQ: XNCR ... for the treatment of autoimmune diseases, asthma and allergic ... Yujiro S. Hata to its board of directors. ... and corporate development is a tremendous asset to our ... chief executive officer of Xencor. "Xencor faces a range ...
(Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... HORSHAM, Pa., Sept. 20, 2011 Verilogue, the ... upcoming presentations highlighting company initiatives, including CareCoach.com, the ... healthcare dialogue between patients, caregivers and their physicians. ... conferences in September: e-Patient Connections; ...
... Sept. 20, 2011 Reportlinker.com announces that a ... catalogue: Rheumatoid Arthritis Market Forecast ... The launch of novel oral drugs and reformulations ... across the seven major markets, rising from $12bn ...
Cached Medicine Technology:Verilogue to Present at Upcoming Health IT and Patient-Focused Conferences 2Rheumatoid Arthritis Market Forecast 2
... needed for quality, comprehensive portable and bedside ... allows you to see up to four ... touch screen allows easy navigation through menus ... temperature., ,Standard features include two channels ...
... all-in-one anesthesia monitor., ,The Cardiocap/5 ... for use in the operating room, ... PACU. The Cardiocap/5 offers full vital ... of oxygenation and circulation to advanced ...
... tool for Clinical Professionals and Researchers., ,S/5 ... easy and efficient way to collect data from ... to days at selectable time intervals. With S/5 ... from the monitor via an interface cable or ...
... for intermediate care., ,The S/5 FM is ... S/5 product line., ,The S/5 FM has ... to grow. The new Patient Side Module (PSM) ... up to 12-lead ECG, NIBP, motion-tolerant SpO 2 ...
Medicine Products: